The Changing Face of Chronic Illness Management in Primary Care: A Qualitative Study of Underlying Influences and Unintended Outcomes
暂无分享,去创建一个
[1] Len Lichtenfeld,et al. Overdiagnosed: Making People Sick in Pursuit of Health , 2011 .
[2] M. S. Kirkman,et al. Response to Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011, Diabetes Care.
[3] Eric G Campbell,et al. Conflicts of interest in cardiovascular clinical practice guidelines. , 2011, Archives of internal medicine.
[4] Michael E. Miller,et al. Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes , 2011 .
[5] H. Brody,et al. The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health , 2011, American journal of public health.
[6] M. Rodwin. Conflicts of Interest and the Future of Medicine: The United States, France, and Japan , 2011 .
[7] Fang Zhang,et al. Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom: interrupted time series study , 2011, BMJ : British Medical Journal.
[8] R. Brumback. White coat, black hat: Adventures on the dark side of medicine , 2011 .
[9] M. Rodwin. Comprar Conflicts of Interest and the Future of Medicine The United States, France, and Japan | Marc A. Rodwin | 9780199755486 | Oxford University Press , 2011 .
[10] Sowmya R. Rao,et al. Physician professionalism and changes in physician-industry relationships from 2004 to 2009. , 2010, Archives of internal medicine.
[11] Mark Woodward,et al. Severe hypoglycemia and risks of vascular events and death. , 2010, The New England journal of medicine.
[12] Y. Ostchega,et al. Recent trends in the prevalence of high blood pressure and its treatment and control, 1999-2008. , 2010, NCHS data brief.
[13] Prevalence of selected risk behaviors and chronic diseases and conditions-steps communities, United States, 2006-2007. , 2010, Morbidity and mortality weekly report. Surveillance summaries.
[14] C. Elliott. White Coat, Black Hat: Adventures on the Dark Side of Medicine , 2010 .
[15] Vicki L Burt,et al. Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008. , 2010, NCHS data brief.
[16] Michael Oldani. Assessing the ‘relative value’ of diabetic patients treated through an incentivized, corporate compliance model , 2010, Anthropology & medicine.
[17] G. Bakris,et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. , 2010, JAMA.
[18] Kalman D. Applbaum. Shadow science: Zyprexa, Eli Lilly and the globalization of pharmaceutical damage control , 2010 .
[19] M. Beach,et al. Cryptosporidiosis surveillance - United States, 2006-2008. , 2010, Morbidity and mortality weekly report. Surveillance summaries.
[20] J. Mold,et al. The Law of Diminishing Returns in Clinical Medicine: How Much Risk Reduction is Enough? , 2010, The Journal of the American Board of Family Medicine.
[21] R. Heine,et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study , 2010, The Lancet.
[22] D. Light,et al. 3. The Commercialization of Medical Decisions: Physicians and Patients at Risk , 2010 .
[23] D. Light. 1. Bearing the Risks of Prescription Drugs , 2010 .
[24] D. Light. The risks of prescription drugs , 2010 .
[25] Rodney A Hayward,et al. New diabetes HEDIS blood pressure quality measure: potential for overtreatment. , 2010, The American journal of managed care.
[26] V. Basevi. Standards of Medical Care in Diabetes—2010 , 2010, Diabetes Care.
[27] D. Aron,et al. Hidden Complexities in Assessment of Glycemic Outcomes: Are Quality Rankings Aligned with Treatment? , 2010 .
[28] S. Tanenbaum. Pay for performance in Medicare: evidentiary irony and the politics of value. , 2009, Journal of health politics, policy and law.
[29] Kalman D. Applbaum. Getting to Yes: Corporate Power and the Creation of a Psychopharmaceutical Blockbuster , 2009, Culture, medicine and psychiatry.
[30] R. Matthews. Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry , 2008, Journal of Nuclear Medicine.
[31] Sheila Leatherman,et al. Lessons From Evaluations of Purchaser Pay-for-Performance Programs , 2008, Medical care research and review : MCRR.
[32] Reamer L. Bushardt,et al. Polypharmacy: Misleading, but manageable , 2008, Clinical interventions in aging.
[33] Joel Lexchin,et al. The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States , 2008, PLoS medicine.
[34] J. Slinn. Prescribing by Numbers: Drugs and the Definition of Disease , 2007 .
[35] Bernard J. Gersh,et al. Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention , 2007, Circulation.
[36] T. Moger,et al. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. , 2007, British journal of clinical pharmacology.
[37] J. Greene. Prescribing by Numbers: Drugs and the Definition of Disease , 2007 .
[38] B. Golomb,et al. Physician Response to Patient Reports of Adverse Drug Effects , 2007, Drug safety.
[39] H. Brody,et al. Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry , 2006 .
[40] T. Cymet,et al. The Truth about Drug Companies: How They Deceive Us and What to Do about It , 2006 .
[41] Lethia Collins Rn Msn Cnor Cfnp. Overdo$ed America: The Broken Promise of American Medicine , 2006 .
[42] J. Kassirer. On the take : how America's complicity with big business can endanger your health , 2005 .
[43] Y. Jang,et al. Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .
[44] Ray Moynihan. Overdo$ed America: The Broken Promise of American Medicine , 2004, BMJ : British Medical Journal.
[45] J. Abramson. Overdosed America: The Broken Promise of American Medicine , 2004 .
[46] Marcia Angell,et al. The Truth About the Drug Companies , 2004 .
[47] Jerry Avorn,et al. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs , 2004 .
[48] Daniel W. Jones,et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.
[49] Ihab Hajjar,et al. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. , 2003, JAMA.
[50] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[51] Andrea Ohldin,et al. The search for value in health care: a review of the National Committee for Quality Assurance efforts. , 2002, Journal of the National Medical Association.
[52] A. Detsky,et al. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. , 2002, JAMA.
[53] B. Rockhill. The privatization of risk. , 2001, American journal of public health.
[54] S. Woolf,et al. New diabetes guidelines: a closer look at the evidence. , 1998, American family physician.
[55] Jerry H Gurwitz,et al. Optimising drug treatment for elderly people: the prescribing cascade , 1997, BMJ.
[56] Hj Norussis,et al. SPSS for Windows , 1993 .
[57] D. Commerce. Statistical abstract of the United States , 1978 .